ロード中...
Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen
Background: Most patients with non-small cell lung cancer (NSCLC) experience disease progression after first-line treatment. The efficacy and safety of the nab-paclitaxel (nab-PTX) and bevacizumab combination as the second or further line of treatment in patients with advanced NSCLC have not been re...
保存先:
| 出版年: | J Cancer |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Ivyspring International Publisher
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7532494/ https://ncbi.nlm.nih.gov/pubmed/33033525 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.47072 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|